



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 691 131 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention

of the grant of the patent:

06.10.1999 Bulletin 1999/40

(51) Int. Cl.⁶: A61K 39/018

(21) Application number: 95201817.4

(22) Date of filing: 04.07.1995

(54) Babesia vaccine

Babesia-Impfstoff

Vaccin à base de babesia

(84) Designated Contracting States:
ES FR GR IT NL PT

(30) Priority: 06.07.1994 EP 94201944

(43) Date of publication of application:
10.01.1996 Bulletin 1996/02

(73) Proprietor: Akzo Nobel N.V.
6824 BM Arnhem (NL)

(72) Inventor:
Schetters, Theodorus Petrus Maria
NL-5432 CD Cuyk (NL)

(74) Representative:
Hermans, Franciscus G.M. et al
P.O. Box 20
5340 BH Oss (NL)

(56) References cited:
EP-A- 0 018 579 EP-A- 0 220 988

- BIOLOGICAL ABSTRACTS, vol. 88, no. 2, 1989
Philadelphia, PA, US; abstract no. 16375, G.
UILENBERG ET AL. 'THREE GROUPS OF
BABESIA CANIS DISTINGUISHED AND A
PROPOSAL FOR NOMENCLATURE.' page AB-
542; & THE VETERINARY QUARTERLY, vol. 11,
no. 1, 1989 pages 33-40,

EP 0 691 131 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] This invention is related to a vaccine against babesiosis, more specifically against canine babesiosis.

5 [0002] Babesiosis, like malaria, is a disease which has a focal character. The reason for this is that the pathogen is transmitted by ticks that feed on a certain reservoir of parasites present in the vertebrate population. Only where ticks are present, babesiosis can occur. On balance, particularly in indigenous animals, the parasite coexists with the host without causing significant disease. In many cases babesiosis is a problem because of man's activities through inbreeding of genetic traits and/or transporting animals to unfamiliar environments where babesiosis is endemic (Callow, L.L and Dalgliesh, R.J., 1982).

10 [0003] In dogs the disease is caused by *Babesia canis* and *Babesia gibsoni*.

[0004] At present three subspecies of *B. canis* are distinguished: *B. c. canis* (transmitted by *Dermacentor* ticks), *B. c. rossi* (transmitted by *Haemaphysalis* ticks) and *B. c. vogeli* (transmitted by *Rhipicephalus* ticks; Uilenberg, G. et al., 1989).

15 [0005] Signs of disease in naturally acquired babesiosis usually begin 7-21 days after infection. These symptoms include: fever, anorexia, depression, anaemia, haemoglobinuria and rapidly developing weakness. Increased lacrimation, salivation and muscle tremor commonly occur. Nervous signs may develop in terminal infections, and death may occur when the disease is left untreated. Severe coagulation disturbances resembling disseminated intravascular coagulation (DIC) have been reported in acute *B. canis* infections (Moore, D.J. and Williams, M.C., 1979). Thrombosis is not common, but small hyaline thrombi, connected with megakaryocytes have been described (Fischer, W. and Scheide-
20 man, H., 1920). It appears that these coagulation disturbances lead to increased erythrocyte-stickiness. As a result the blood passage through the microvasculature is hampered, resulting in congestion of internal organs and decreased packed cell volumes (PCV). This might impair the oxygen supply to certain tissues and subsequently lead to tissue damage as a result of anoxia (Malherbe, W.D. and Parkin, B.S., 1951; Basson, P.A. and Pienaar, J.G., 1965; Jacquier, C., 1973). Evidence from congestion in *B. canis* infections comes from experiments in which dogs were chemothera-
25 peutically treated. Some of these animals restore the packed cell volume in two days from 25-35%, which is associated with shrinkage of the spleen to normal measures.

25 [0006] The three subspecies of *B. canis* differ with respect to their pathogenicity (Uilenberg et al., 1989). The North-African *B. c. vogeli* strains provoke only mild disease, which usually does not require treatment (like the Australian *B. canis* strains). European *B. c. canis* strains are more pathogenic than the North-African parasite. In our experiments with the *B. c. canis* A strain, approximately half of the animals required chemotherapeutic treatment after infection (Schetters et al., 1994). The South-African *B. c. rossi* strains are most pathogenic, a feature observed already very early (Nuttal, 1904). Using the South-African *B. c. rossi* strain naive dogs developed progressing disease characterised by exponential parasite growth. In contrast, parasitaemia in dogs infected with European *B. c. canis* usually is limited. In the latter, congestion appears to be the main pathological feature.

30 [0007] At the moment a vaccine for *Babesia* is prepared from the supernatant of a culture of a strain of *Babesia canis*, as is described in US-A-4 777 036. However, such a vaccine contains only antigens of this strain of this particular sub-
35 species of *B. canis*. It appears that such a vaccine gives in general little protection against infections with (wild type) *B. canis* (Lepetit, C., *Piroplasmose canine et vaccination Pirodog*, Doctoral Thesis, Univ. of Nantes, 1988). The author of the thesis gives three possible causes of this failure of protective immunization:

40 1. the sensitivity of the dogs with respect to vaccination;
2. the type of immune effector mechanism induced by vaccination;
3. the antigenic diversity of *Babesia*.

45 [0008] Strain dependency of this type of vaccination against *Babesia bovis* in cattle has been shown (Ristic and Montenegro-James, 1988). A similar finding has been made in vaccination of dogs (Sibinovic et al. 1967 and Schetters et al. 1995). Herein it is described that the antigenic diversity of *Babesia* has a great impact on the efficacy of vaccination: if the vaccine is made from the supernatant of a culture of a single strain of *Babesia* it only protects against challenges with the homologous strain.

50 [0009] Vaccines containing whole, attenuated *Babesia* parasites always harbour the danger that the parasites again become virulent and thus spread the disease instead of curing it. Therefore, it is preferable to use a subunit vaccine.

[0010] Thus there remains the desire for a vaccine which is not infective, which can be easily produced and which yet can give protection against heterologous (wild-type) challenge infection.

[0011] Our invention now is a vaccine for protection against babesiosis comprising antigens from *B. canis*, characterised in that it comprises antigens from *B. canis rossi* and antigens from another *B. canis* subspecies.

[0012] Antigens in this respect are biological entities obtainable from *Babesia* in any way, that are capable of eliciting an immunological response in dogs after administration. Antigens can comprise both somatic parasitic molecules and molecules excreted or secreted by the parasite. Also host molecules altered as a result of infection with *Babesia* are

included in this definition.

[0013] Known subspecies of Babesia canis next to B. c. rossi are B. c. canis and B. c. vogeli (Uilenberg, G. et al., 1989). From B. c. canis at least three different strains have been isolated, denominated strain A, strain B and the strain used in the commercial vaccine 'Pirodog®'.

5 [0014] The vaccine according to the invention may comprise an antigen in a pure form, optionally in the presence of a veterinary acceptable carrier. The antigen can optionally be covalently bound to a non-related protein.

[0015] Such a vaccine does not only protect against infections with B. c. canis strain from which the antigens in the vaccine have been isolated (homologous protection), but it surprisingly also gives protection to infections with heterologous B. c. canis strains.

10 [0016] The model of homologous protection has been indicated by Lepetit (*supra*), and is demonstrated by our experiments in which vaccination with antigens from subspecies B. c. canis strain A does not protect against infections with B. c. canis strain B (Schetters et al., 1995). Also vaccination with Pirodog® (commercially available and produced from a culture of another B. c. canis subspecies strain) does not protect against challenge with either B. c. canis strain A or B. c. canis strain B. Furthermore, vaccination with antigens of a strain of B. c. rossi alone is - in contrast to the findings 15 after infection with a wild-type strain - not protective for challenges with any strain of B. c. canis.

[0017] From our experiments it surprisingly appeared that vaccination with a vaccine comprising both antigens from supernatants of cultures of B. c. rossi and B. c. canis strain A gave adequate protection upon challenge with B. c. canis strain B parasites. This means that such a vaccine enables heterologous protection.

20 [0018] Preferably the vaccine is prepared from soluble antigens which are released in the medium of a culture of Babesia in for example erythrocytes. For this culture to blood of an infected animal an anticoagulant is added and a cell suspension from this sample is grown in culture flasks on a medium suitable for growth. Soluble antigens, i.e. antigens which do not precipitate in an aqueous solution such as culture medium, are collected.

25 [0019] Preferably the antigens will be derived from the culture supernatant, which is harvested. The antigens can be concentrated by filtering or evaporation of the medium, or any other suitable way.

[0020] In addition to an immunogenically effective amount of the antigen the vaccine may contain a pharmaceutically acceptable carrier or diluent. Examples of pharmaceutically acceptable carriers or diluents useful in the present invention include stabilizers such as SPGA, carbohydrates (e.g. sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein containing agents such as bovine serum or skimmed milk and buffers (e.g. phosphate buffer).

30 [0021] The immunogenicity of the antigens of the invention can be enhanced by cross-linking or by coupling to an immunogenic carrier molecule (i.e. a macromolecule having the property of independently eliciting an immunological response in a recipient, to which the antigens of the invention can be linked, for example β -galactosidase, protein A, prochymosine, blood clotting factor Xa, etc.).

35 [0022] Coupling to the carrier molecule can be carried out using methods well known in the art, the exact choice of which will be dictated by the nature of the antigen and the carrier molecule used. When the immunogenic carrier molecule is a protein, the Babesia antigens can be coupled, e.g. using water soluble carbodiimides such as dicyclohexylcarbodiimide, or glutaraldehyde.

[0023] Coupling agents such as these can also be used to cross-link the antigens to themselves without the use of a separate carrier molecule. Such cross-linking into peptide aggregates can also increase immunogenicity.

40 [0024] Optionally, one or more compounds having adjuvant activity may be added to the vaccine. Suitable adjuvants are for example aluminium hydroxide, phosphate or oxide, oil-emulsions (e.g. of Bayol F^(R) or Marcol 52^(R)), or saponins e.g. QuilA^(R).

[0025] The vaccine according to the present invention can be given *inter alia* subcutaneously or intramuscularly.

45 [0026] The optimal effective amount to be administered will vary depending on the age and weight of the animal and mode of administration of the vaccine. A suitable dose will be the amount of antigenic material produced by $2 \cdot 10^7$ - $2 \cdot 10^9$ parasites in 12 hours culturing, of which parasites preferably half is B. c. rossi and the other half is an other B. canis subspecies.

[0027] The method to prepare a vaccine according to the invention will, in general, comprise the steps of

50 - culturing the Babesia parasites in a suitable medium;
 - harvesting the antigenically active substances from this medium;
 - admixing said substances with pharmaceutically acceptable excipients.

Legend to the figures.

55

[0028]

Fig. 1. The development of antibody reactivity against infected erythrocytes upon vaccination with a monovalent

vaccine and subsequent challenge infection. Data represent the mean antibody titre as determined in slide-ELISA from groups of animals.

5 Fig. 2. The effect of vaccination with a monovalent vaccine on parasitaemia after homologous or heterologous challenge infection. Data represent the mean values of groups of animals and are log transformed.

10 Fig. 3. The effect of vaccination with a monovalent vaccine on the peripheral red blood cell number after homologous or heterologous challenge infection. Data are expressed as packed cell values (PCV) and represent the mean value of groups of animals. Animals that were chemotherapeutically treated were from that day on omitted from the group.

15 Fig. 4. The effect of different doses of monovalent vaccine on the peripheral red blood cell number after homologous challenge infection. Data are expressed as packed cell values (PCV) and represent the mean value of groups of animals. No animals were chemotherapeutically treated.

20 Fig. 4a. The effect of vaccination with monovalent *B. c. rossi* on the PCV value of dogs after challenge infection with heterologous *B. c. canis* B parasites. Data are expressed as packed cell values and represent the mean value of groups of animals. Animals that were chemotherapeutically treated were from that day on omitted from the group.

25 Fig. 5. The effect of vaccination with a combination vaccine on parasitaemia after challenge infection. Data represent the mean values of groups of animals, and are log transformed.

25 Fig. 6. The antibody response against *Babesia canis*-infected erythrocytes upon vaccination with a combination vaccine. Data represent end-point titres of pooled serum samples.

25 Fig. 7. The effect of combination-vaccination on the peripheral red blood cell number after heterologous challenge infection. Data are expressed as packed cell values (PCV) and represent the mean value of groups of animals. No animals were chemotherapeutically treated.

30 EXAMPLES

Materials and methods

Animals

35 [0029] Dogs (Beagle) of approximately 7 months of age and of both sexes were used. They were kept at the dog-unit of Intervet International (Boxmeer, The Netherlands). They received a standard amount of food daily. Drinking water was supplied ad libitum. Experimental groups were formed assuring an equal distribution of animals according to litter and sex.

40 Parasites

45 [0030] Two different *Babesia canis* isolates (A and B) were used. They both originated from France. *Babesia canis rossi* originates from South-Africa (Uilenberg et al., *supra*). Isolates were stored as stablitate in liquid nitrogen, and passed once through a splenectomised dog before in vitro culture or infection. Challenge infections were done with blood from infected dogs.

Challenge infection

50 [0031] Three weeks after the booster injection with vaccine dogs were challenged with blood of an infected dog. The blood was taken by venapuncture from the vena jugularis using heparin to prevent clotting. The blood was washed once in *Babesia* medium (see below). A volume of blood, containing 2.10^6 infected erythrocytes was injected intravenously into recipient dogs.

55 *Parasitaemia*

[0032] The parasitaemia is expressed as the log number of red blood cells infected with *Babesia* parasites per 10^5 erythrocytes in the peripheral blood (taken by venapunction from the vena jugularis according to Jarra and Brown,

1985). It was read from blood smears stained with May-Grunwald/Giemsa solutions.

Haematocrit

5 [0033] The haematocrit value is expressed as packed cell volume (PCV) of a sample of venous blood taken from the vena jugularis. A haematocrit capillary was filled with heparinised blood and centrifuged in a haematocrit centrifuge for 5' at 10,000 rpm. The packed cell volume was read using a haematocrit reader (Hawksley).

Serum

10 [0034] Serum was prepared according to routine procedures. Blood was collected from the vena jugularis and allowed to clot at room temperature for at least 60 minutes. Cellular contaminants were removed by centrifugation (1500g, 10', room temperature). Serum was stored at -70°C.

15 [0035] *Plasma*

Plasma was prepared from heparinised blood from the vena jugularis. The sample was kept on ice. Cells were pelleted by centrifugation (1500g, 10', 4°C), and the clear plasma aspirated. It was stored at -70°C.

20 [0036] *Babesia medium*

RPMI-1640 (Gibco), supplemented with HEPES (40 mM), sodiumpyruvate (1mM), L-glutamine (2mM) and sodium hydrogen carbonate (1 g/l) was adjusted to pH 7.4, and used for in vitro culture of the parasite

25 [0037] *In vitro culture*

The parasite was cultured in vitro for a limited period of time as essentially described (Schetters et al., 1992.). In short, blood of an infected dog was withdrawn by venapuncture, collected in a tube containing heparin to prevent clotting, and immediately put on ice. The blood was washed and a cell suspension of 5% packed cell volume (PCV) and 30 0.3% parasitaemia was prepared in complete Babesia medium (which contains 40% v/v normal dog serum). A volume of 40 ml was cultured in 75 cm² culture flasks (Greiner). The flasks were gassed with commercial gas mixture containing 2% (v/v) O₂, 5% (v/v) CO₂ and 93% (v/v) N₂ and put at 38.7°C. Twice a day the cultures were transferred to 50 ml tissue culture tubes (Falcon) and centrifuged (400g, 5', 4°C). Of each culture 25 ml of the supernatant was collected, and replaced by fresh Babesia medium, prewarmed in a 37°C waterbath. The cultures were gassed and incubation 35 resumed. Supernatants were collected at 48, 60 and 72 hours of culture, pooled and concentrated to one-thenth the original using a tangential flow apparatus (Millipore) with a filter of 10kD cutoff.

Vaccine formulations

40 [0038] Vaccines were obtained from the supernatant of Babesia cultures and contained one ml of concentrated supernatant of a culture of 2.10⁸ parasited erythrocytes per ml. Saponin (Quil A^(R), Superfos) was added to a final concentration of 0.5 mg/ml.

[0039] Combination vaccines were composed by mixing one ml of concentrated supernatant of two different cultures to a total volume of 2 ml.

45 [0040] Saponin adjuvant control was obtained by diluting saponin in physiological salt solution to a concentration of 0.5 mg/ml.

Vaccination

50 [0041] Groups of five dogs were formed assuring an even distribution of litter and sex. Serum was collected prior to vaccination, and at weekly intervals during the whole experimental period (i.e. vaccination and challenge). Animals received a priming injection with vaccine and three weeks later a booster injection, subcutaneously.

Antibody titres (SELISA)

55 [0042] Antibody titres against parasited erythrocytes were determined using the slide-ELISA technique described earlier (Schetters et al., 1992). In short, serum dilutions are incubated on acetone-fixed blood smears of Babesia canis infected dogs. The immunoglobulin bound is visualised using a biotin-streptavidin-peroxidase detection system. Twofold

serial dilutions are tested and titres are expressed as the last dilution step which gave a positive reaction (blue stain).

Clinical examination

5 [0043] After challenge infection all experimental animals were examined daily for clinical signs. Special attention was given to behaviour, spleen size, size of lymph nodes, colour of the mucous membrane of the eyelid, and the capillary refill time. The clinical score was determined as described earlier (Schetters et al., 1994). Dogs that had to be chemotherapeutically treated were given the maximal clinical score (=6). Chemotherapeutic treatment was considered when the health condition of the animal rapidly deteriorated. Dogs were injected with 0.6 ml Imizol (Pitman-Moore, Coopers)

10 for two consecutive days. Within three days after this treatment no parasites are detectable in the peripheral blood.

RESULTS

*Example 1. Vaccinations with *B. c. canis*.*

15 [0044] Groups of five dogs were vaccinated with Intervet *B. c. canis* A vaccine as prepared above and subsequently challenged with homologous or heterologous parasites. After priming and boosting all animals showed antibody responses against parasitised erythrocytes. The mean antibody titre of the two vaccinated groups was comparable (Figure 1). Upon challenge infection both groups of vaccinated animals exhibited slight decreases of antibody titres against parasitised erythrocytes. In both groups the antibody response was boosted by challenge infection. There was a one to two day difference between these booster responses; animals challenged with homologous parasites responding earlier (day 3-4) than those challenged with heterologous parasites (day 5).

20 [0045] Vaccination did not affect the course of parasitaemia after challenge infection irrespective of the parasite isolate used (Figure 2). The prepatent period was two days, thereafter parasites were observed in the blood, and parasitaemia peaked at day 6 after infection. After that period of time parasitaemia declined, following an irregular pattern. Clear recrudescences were not observed, although there was a tendency of increased parasitaemia at days 9 and 12 of infection. In general, animals challenged with *B. c. canis* B parasites suffered from higher parasitaemias as compared to those infected with *B. c. canis* A parasites (Table I). None of the vaccinated animals that were challenged with homologous parasites required chemotherapeutical treatment. In contrast, in each of the other groups two out of five animals

25 had to be treated for severe life-threatening babesiosis.

30 [0046] All animals (vaccinated or not) suffered from anaemia as a result of challenge infection (Figure 3). The first four days after infection the slope of the haematocrit values of the vaccinated animals was less steep than that of controls. From day 5 after infection onwards, the vaccinated animals that were challenged with homologous parasites diverted from the other animals, and from day 7 onwards there was no further decrease of haematocrit values in this group. Vaccinated animals that were challenged with heterologous parasites also showed signs of recovery from day 7 onwards. The haematocrit values of animals that had received adjuvant alone dropped further for another two days. At that time point there was an initially rapid increase of haematocrit values, followed by a period of more gradual recovery from day 11-12. When the maximal decrease of PCV for each individual animal was calculated it appeared that significantly less decreased values were observed in vaccinated animals that had experienced a homologous challenge infection. This

35 40 was not found for the vaccinated animals that were challenged with heterologous parasites (Table I).

[0047] From this it follows that from vaccination with antigens of a particular subspecies of *Babesia canis* no protection against heterologous infection can be obtained.

Example 2. Dose-response relationship.

45 [0048] Groups of five dogs were vaccinated with three different doses of vaccine prepared from cultures of *B. c. canis* isolate A. The three doses were: normal dose, a 5x diluted and a 5x concentrated dose. The amount of adjuvant used was the same for every injection (1 mg Quil A/dose). Animals were vaccinated twice, with a three week interval. Three weeks after the booster injection animals were challenged with homologous parasites. It appeared that the animals vaccinated with the highest amount of antigen were best protected (fig. 4 and Table II), although differences were small.

50 [0049] Thus, there is a broad range of antigen concentration which yields comparable levels of protection after vaccination.

*Example 3. Vaccination with *B. c. rossi* and heterologous challenge.*

55 [0050] Groups of three dogs were vaccinated with a monovalent vaccine prepared from *B. c. rossi* culture supernatants. Animals received two injections, three weeks apart. Three weeks after the booster injection they were challenged with $2 \cdot 10^6$ infected erythrocytes from *B. c. canis* isolate B. Animals had to be treated for severe clinical babesiosis at

day 7 after challenge infection. The maximal decrease of PCV value was at that time 48.5 (12.0) and was not measured further because the animals received chemotherapeutical treatment. At that time the antibody titer was 4.0 as measured by slide-ELISA. In this experiment no control infections were carried out.

[0051] In a second experiment, groups of five dogs were vaccinated four times with three week intervals using a monovalent vaccine prepared of *B. c. rossi* culture supernatants. Upon vaccination the animals developed antibodies against *B. canis* parasites. After challenge infection with heterologous *B. c. canis* parasites it appeared that although there appeared to be an initial effects on the dynamics of the PCV values (slightly less decrease three to four days after challenge infection; see figure 4a), all animals had to be treated chemotherapeutically to prevent death.

[0052] From these experiments follows that vaccination with *B. c. rossi* alone does not give protection against heterologous challenges.

*Example 4. Vaccination with a combination vaccine based on antigens from culture supernatants of *B. c. canis* isolate A and *B. c. rossi*.*

[0053] Groups of five dogs were vaccinated with a vaccine preparation based on antigens from *B. c. canis* isolate A culture and *B. c. rossi* culture. Of each of the components one dose was administered (the animals thus receiving a double antigen dose). Animals were injected twice, three weeks apart. Three weeks after the booster injection animals were challenged with heterologous parasites (*B. c. canis* isolate B).

[0054] Vaccination did not affect the course of infection significantly (Figure 5). The prepatent period was one day for both groups of animals. Parasitaemia increased rapidly, peaked at day three after infection, and subsequently declined. By day 11 parasitaemia was undetectable in both groups.

[0055] Vaccination induced antibodies against parasitised erythrocytes. The antibody titre of pooled plasma was 6 at the time of challenge infection (Figure 6). After challenge infection the antibody titre dropped, but from day four onwards increased rapidly to levels of about 8. Importantly, this type of response was comparable to the response found after homologous challenge infections (*supra*, Figure 1), indicating that vaccination with the combination vaccine provoked an effective memory response upon heterologous challenge infection.

[0056] Both groups of animals suffered from anaemia after challenge infection. The PCV value dropped the first four days in an identical manner (Figure 7). From that day onwards the PCV value from the vaccinated animals did not drop significantly anymore. This coincided with the onset of the memory antibody response (Figure 6). PCV values of the control animals decreased further, and the animals had to be treated chemotherapeutically. The maximal decrease of PCV value of the vaccinated group was significantly less than that of the control group (Table III). The dynamics of the PCV values of the vaccinated animals resembled that of vaccinated animals that were challenged with homologous parasites (Figure 3). No clinical scores were obtained.

[0057] It appeared that the PCV drop of vaccinated dogs was significantly less (42.1 ± 5.5) than controls (53.1 ± 4.5), see also Fig. 5.

Table I

The effect of vaccination with Intervet canis A preparations on the haematocrit, parasitic load and clinical score values after challenge with <i>Babesia canis canis</i> isolate A or <i>Babesia canis canis</i> isolate B parasites.				
Treatment	Challenge infection	Max decr PCV ^a	Parasitic load	Max clin score
Intervet canis A	canis A	44.9 (5.3)	4.0 (1.2)	2.6 (1.1)
Control	canis A	60.6 (12.1)	5.4 (1.5)	4.0 (1.9)
Intervet canis A	canis B	54.7 (10.1)	5.9 (1.5)	4.1 (2.0)
Control	canis B	55.6 (10.7)	7.0 (1.3)	4.1 (1.9)

^aData represent the group mean values (\pm sd).

Table II

The effect of vaccination with different doses of Intervet canis A preparations on the haematocrit, antibody titre and clinical score values after challenge with Babesia canis canis isolate A.				
Treatment	Challenge infection	Max decr PCV ^a	antibody titre	Max clin score
Antigen 1/5	canis A	42.0 (10.1)	5.0 (0.7)	2.3 (1.1)
Antigen 1/1	canis A	39.5 (3.5)	7.0 (0.7)	1.7 (0.9)
Antigen 5/1	canis A	35.1 (7.3)	7.3 (0.5)	1.6 (1.0)
Control Quil A	canis A	62.2 (8.0)	1.2 (0.5)	4.4 (1.7)

^aData represent the group mean values (\pm sd).

Table III

The effect of vaccination with a combination vaccine preparation on the hematocrit and antibody titre after challenge with Babesia canis canis isolate A Parasites.			
Treatment	Challenge infection	Max decr PCV ^a	Antibody titre ^b
Combination	canis A	42.1 (5.5)	6.0
Adjuvant only	canis A	53.1 (4.5)	1.0

^aData represent the group mean values (\pm sd).

^btitre measured from pooled serum. No sd available.

References

[0058]

Basson, P.A. and Pinnaar, J.G. (1965) Canine babesiosis: a report on the pathology of three cases with special reference to the 'cerebral' form. *J. South Afric. Med. Ass.* 36, 333.

Callow, L.L. and Dalglish, R.J. (1982) Immunity and immunopathology in babesiosis. In: *Immunology of parasitic infections*. Cohen, S. and Warren, K. (eds.) Blackwell Scientific Publ., Oxford, pp. 475.

Fisher, W. and Scheideman, H. (1920) *Klinisches und Histologische Untersuchungen über Hunde Babesiose*. *Zentralbl. f. Bakt. Parasit. Infekt. u. Hygiene, Originale* 84, 35.

Jacquier, C. (1973) Piroplasmose canine: polymorphisme clinique. *Schweiz. Arch. f. Tierheilk.* 115, 121.

Jarra, W. and Brown, K.N., (1985) *Parasite Immunol.* 7, 595

Lepetit, C. (1988) *Piroplasmose canine et vaccination Pirodog*. Thèse, Ecole Nationale Veterinaire de Nantes.

Malherbe, W.D. and parkin, B.S. (1951) Atypical symptomology in Babesia canis infection. *J. South Afric. Vet. Med. Ass.* 22, 25.

Moore, D.J. and Williams, M.C. (1979) Disseminated intravascular coagulation: a complication of Babesia canis infection in the dog. *J. South Afr. Vet. Ass.* 50, 265.

Nuttal, G.H.F. (1904) Canine piroplasmosis.

Ristic, M. and Montenegro-James, S. (1988) In: *Babesiosis of domestic animals and man*. Ed: Ristic, M. CRC Press Inc. Boca Raton, Florida, pp. 163

Schetters, Th.P.M. et al. (1992) Vaccination of dogs against Babesia canis infection using antigens from in vitro culture. *Parasite Immunol.* 14, 295-305.

Schetters, Th.P.M. et al. (1994) Vaccination of dogs against Babesia canis infection with emphasis on clinical babesiosis. *Vet. Parasitol.* 52(3-4), 219-233.

Schetters, Th.P.M. et al. (1995) Strain variation limits protective activity of vaccines based on soluble Babesia canis antigens. *Parasite Immunol.* 17, xx-xx.

Sabinovic, K.H. et al. (1967) A study of some of the physical, chemical and serological properties of antigens from sera of horses, dogs and rats with acute babesiosis. *J. Parasitol.* **53**, 919.

Uilenberg, G. et al. (1989) Three groups of *Babesia canis* distinguished and a proposal for nomenclature. *Vet. Quart.* **11**, 33.

5

Claims

1. Vaccine for the protection of dogs against babesiosis comprising antigens from *B. canis*, characterised in that it comprises antigens from *B. canis* rossi and antigens from another *B. canis* subspecies.
- 10 2. Vaccine according to claim 1, characterized in that it comprises antigens from *Babesia canis* rossi and *Babesia canis* canis.
- 15 3. Vaccine according to claim 1 or 2, characterized in that the antigens are soluble antigens.
4. Vaccine according to claim 3, characterized in that the antigens are derived from culture supernatants.
- 15 5. Vaccine according to any of claims 1 to 4, characterized in that it also comprises a carrier or an adjuvant.
- 20 6. Method for the preparation of a vaccine according to one of claims 1-5, characterized in that it comprises the steps of:
 - culturing the *Babesia* parasites in a suitable medium;
 - harvesting the antigenically active substances from this medium;
 - 25 - admixing said substances with pharmaceutically acceptable excipients.

Patentansprüche

1. Impfstoff zum Schutz von Hunden gegen Babesiosis, welcher Antigene von *B. canis* umfasst, dadurch gekennzeichnet, dass er Antigene von *B. canis* rossi und Antigene von einer anderen *B. canis*-Subspezies umfasst.
- 30 2. Impfstoff gemäss Anspruch 1, dadurch gekennzeichnet, dass er Antigene von *Babesia canis* rossi und *Babesia canis* canis umfasst.
- 35 3. Impfstoff gemäss Anspruch 1 oder 2, dadurch gekennzeichnet, dass die Antigene lösliche Antigene sind.
4. Impfstoff gemäss Anspruch 3, dadurch gekennzeichnet, dass die Antigene von Kulturüberständen stammen.
5. Impfstoff gemäss einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, dass er ausserdem einen Träger oder ein 40 Adjuvans umfasst.
6. Verfahren zur Herstellung eines Impfstoffes gemäss einem der Ansprüche 1-5, dadurch gekennzeichnet, dass es die Schritte
 - Züchten der *Babesia*-Parasiten in einem geeigneten Medium;
 - Ernten der antigenaktiven Substanzen aus diesem Medium;
 - 45 - Mischen der genannten Substanzen mit pharmazeutisch annehmbaren Arzneimittelträgernumfasst.

50

Revendications

1. Vaccin pour la protection des chiens contre la babésiose comprenant des antigènes de *B. canis* caractérisé en ce qu'il comprend des antigènes provenant de *B. canis* rossi et des antigènes provenant d'une autre sous-espèce de *B. canis*.
- 55 2. Vaccin selon la revendication 1 caractérisé en ce qu'il comprend des antigènes provenant de *Babesia canis* rossi et de *Babesia canis* canis.

3. Vaccin selon les revendications 1 ou 2, caractérisé en ce que les antigènes sont des antigènes solubles.
4. Vaccin selon la revendication 3, caractérisé en ce que les antigènes proviennent de surnageants de cultures.
5. Vaccin selon l'une quelconque des revendications 1 à 4, caractérisé en ce qu'il comprend aussi un support ou un adjuvant.
6. Procédé pour la préparation d'un vaccin selon l'une quelconque des revendications 1 à 5, caractérisé en ce qu'il comprend les étapes de:
10
 - culture des parasites Babesia dans un milieu convenable;
 - récolte des substances ayant une activité antigénique à partir de ce milieu;
 - mélange des dites substances avec des excipients acceptables du point de vue pharmaceutique.

15

20

25

30

35

40

45

50

55

Figure 1.




Figure 2




Figure 3




Figure 4




Figure 4a.




Figure 5




Figure 6




Figure 7

